Inferra AIResearch Tools

Inferra AI / Company / PACS

Pacs Group, Inc.

PACS · Health Care

Last earnings Aug 4, 2026

Key results

Revenuequarter

$1.42 billion

First Quarter 2026 Financial Highlights Revenue was $1.42 billion, an increase of 11.2% over prior year.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Net incomequarter

$80.7 million

Net income was $80.7 million, an increase of $52.3 million, or 184.2% from $28.4 million in the prior-year period.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

SNF revenuequarter

8.0%

1 First Quarter 2026 Select KPIs On a same-store basis, which includes the 284 skilled nursing facilities ( SNFs ) operated by the Company as of the beginning of 2025, SNF revenue increased 8.0% in the first quarter of 2026 compared to the prior-year period.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

$ 80,695 $ 28,472 Net Income Per Share Attributable To PACS Group, Inc.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

AI analysis

Q1 2026 · reported May 11, 2026

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Revenue · Q1 2026
$1.42B
EX-99 · May 11, 2026
Net income · Q1 2026
$80.7M
EX-99 · May 11, 2026

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · May 11, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ1 2026Prior qtrYear ago
Revenue$1.42 billion——
Net income$80.7 million——
SNF revenue8.0%——

EX-99 · May 11, 2026

Guidance · company-stated

Direction: Raised

Company outlook

“Revised 2026 Business Outlook Given our strong start to the year and continued excellent performance across both ramping and mature cohorts, we are increasing our full-year 2026 Adjusted EBITDA guidance to a range of $605 million to $625 million, up from our prior 1 Adjusted EBITDA and Adjusted EBITDAR are Non-GAAP Financial Measures.”

Revenue$5.65 billion

“Despite this change, we are reaffirming our revenue guidance of $5.65 billion to $5.75 billion, which previously included approximately $120 million of expected acquisition-related revenue.”

Midpoint vs latest-quarter revenue+297.9%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Share Repurchase Authorization The Company s Board of Directors approved a $250 million share repurchase authorization, effective May 7, 2026.

Repurchases may be made from time to time in the open market, in privately negotiated transactions, or otherwise.

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue +297.9% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Reports First Quarter 2026 Results Conference Call and Webcast Scheduled for Tomorrow, May 12, 2026, at 11 30 am ET

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Company outlook: “Revised 2026 Business Outlook Given our strong start to the year and continued excellent performance across both ramping and mature cohorts, we are increasing our full-year 2026 Adjusted EBITDA guidance to a range of $605 million to $625 million, up from our prior 1 Adjusted EBITDA and Adjusted EBITDAR are Non-GAAP Financial Measures.”

Revenue: “Despite this change, we are reaffirming our revenue guidance of $5.65 billion to $5.75 billion, which previously included approximately $120 million of expected acquisition-related revenue.”

Company outlook — Raised (“increasing”)
“Revised 2026 Business Outlook Given our strong start to the year and continued excellent performance across both ramping and mature cohorts, we are increasing our full-year 2026 Adjusted EBITDA guidance to a range of $605 million to $625 million, up from our prior 1 Adjusted EBITDA and Adjusted EBITDAR are Non-GAAP Financial Measures.”

Revenue — Reiterated (“reaffirming”)
“Despite this change, we are reaffirming our revenue guidance of $5.65 billion to $5.75 billion, which previously included approximately $120 million of expected acquisition-related revenue.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Share Repurchase Authorization The Company s Board of Directors approved a $250 million share repurchase authorization, effective May 7, 2026.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Repurchases may be made from time to time in the open market, in privately negotiated transactions, or otherwise.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

The amount and timing of repurchases, if any, will depend on several factors, including the Company s stock price performance, ongoing capital allocation priorities, contractual restrictions, and general market conditions.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

The share repurchase authorization does not have a fixed expiration date, does not obligate the Company to acquire any particular amount of common stock, and may be modified, suspended, or terminated at any time at the discretion of the Company s Board of Directors.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Establishing a share repurchase authorization provides us with an important capital allocation tool and the flexibility to repurchase shares opportunistically when conditions warrant, said Hendrickson.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

CREDIT FACILITIES The Company maintains a revolving credit facility between the Company and certain of its subsidiaries, and Truist Bank as administrative agent (Administrative Agent) and a syndicate of lenders (the Amended and Restated Credit Facility).

SEC original ↗Pacs Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Strategy & priorities

1 This result includes approximately $16.3 million of net EBITDA benefit from payments received under California s Workforce Quality Incentive Program ( WQIP ), a performance-based program focused on quality of care, workforce investment and health outcomes.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Our performance reflects PACS s core strengths our commitment to care, clinical excellence, operational quality, industry-leading talent, and a strategy built for sustainable growth, said Jason Murray, PACS s Chief Executive Officer.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

We also strengthened our balance sheet during the quarter, increasing revolver availability and maintaining low net leverage of approximately 0.1x, while deploying $86.5 million into strategic real estate investments.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

While we are excluding future acquisitions from our guidance, we continue to see a healthy pipeline of acquisition opportunities and are actively engaged in evaluating potential transactions that align with our strategic and financial criteria, said Hendrickson.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

The Company continues to execute on its strategy of expanding its footprint through a balanced approach to leasing and acquiring real estate.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Risks & headwinds

These payments were not included in the Company s previously issued guidance due to uncertainty regarding the amount and timing of receipt.

SEC original ↗Pacs Group, Inc. — Earnings release (8-K exhibit)EX-99May 11, 2026

Legal Proceedings 46 Item 1A.

SEC original ↗Pacs Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Company determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors.

SEC original ↗Pacs Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The operations added by the Company are frequently underperforming or moderately-performing financially and may have regulatory and clinical challenges to overcome.

SEC original ↗Pacs Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

32 documents

Earnings releases

9 documents

Presentations

0 documents

No presentations for Pacs Group, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Pacs Group, Inc. are held in this edition of the library.

Mentioned by

2 companies

Other tracked companies whose held documents mention Pacs Group, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.